TRVI Trevi Therapeutics, Inc.

NASDAQ
$13.51

Trevi Therapeutics, Inc. (TRVI) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.3% since its last earnings release on November 9, 2026.

Trevi Therapeutics Reported In-line with Estimates
Monday, November 9, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.15)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $13.93

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.